The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Medically reviewed by Katlein Franca, MD Eczema is a chronic (long-lasting) inflammatory condition that causes rashes of scaly, irritated, itchy, dry skin. Affected areas can change color and harden.

The kidneys are responsible for filtering waste from the blood, balancing fluids, and managing minerals like calcium and ...

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...

The FDA has approved Sanofi and Regeneron’s Dupixent as a treatment for adults with bullous pemphigoid, a rare chronic autoimmune skin condition that causes severe itching, painful blisters and open ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

Ron Reimink knew how uncomfortable and annoying swimmer’s itch could be. He spent much of his adult life trying to eradicate ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

Subjects in the trial saw clearance or near-clearance of skin nodules, as measured by the Investigator’s Global Assessment ...